858 Therapeutics
Dr. Gretchen Bain is the SVP of Biology and a cofounder of 858 Therapeutics with 20 years of drug discovery research experience leading all aspects of biology and non-clinical pharmacology. Gretchen began her career at Merck Research Labs and transitioned into biotech in 2005 as Executive Director of Biology at Amira Pharmaceuticals. At Amira, Gretchen contributed to the development of several clinical-stage small molecule therapeutics to treat inflammation and fibrosis and directed the efforts of the LPA1 receptor antagonist program that led to the acquisition of Amira by BMS. In 2012, Gretchen joined PharmAkea Therapeutics as a founding scientist where she and her team contributed to the discovery and development of anti-fibrotic therapies, including small molecule inhibitors of LOXL2 and Autotaxin that were acquired by Galecto Biosciences and Blade Therapeutics, respectively. Prior to 858 Therapeutics, Gretchen was VP of Biology at Jecure Therapeutics, a company that was acquired by Genentech in 2018 for its NLRP3 inflammasome inhibitor program.
Gretchen received a B.A. in Biology from Pomona College and a Ph.D. in Biology from University of California, San Diego.
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.